OneCell Diagnostics is now 1Cell.Ai
OneCell Diagnostics is now 1Cell.Ai
OncoTarget® is a disease-specific targeted NGS panel designed to identify key genomic alterations in major cancers, including Bladder, Breast, Colon, GI, Lung, Melanoma, Ovary, Prostate, Rectal, and Thyroid.
It offers a practical, affordable solution for guiding personalized therapy decisions in real-world clinical practice.
OncoTarget® focuses on detecting guideline-recommended, clinically actionable mutations — making precision oncology more accessible, affordable, and easy to implement across India’s healthcare landscape.
Affordable targeted genomic testing customized to major cancer types
Deep sequencing of critical disease-specific genes
Easily understandable reports for quicker treatment planning
Option to customize up to 20 genes per cancer type
Optional add-on for PD-L1 expression testing (tissue only)
Analysis and active reporting powered by the iCare™ AI platform
Hybrid capture-based sequencing focused on clinically relevant genes, reducing unnecessary data and cost.
Ability to customize up to 20 high-priority genes for each cancer type based on clinical need.
Proprietary AI-based platform simplifies data interpretation, providing clear clinical recommendations aligned with NCCN, ASCO, and ESMO guidelines.
Reports include tiered variant classification, pharmacogenomics insights (limited to DPYD), and appropriate therapy suggestions.
Guide therapy selection based on actionable genomic mutations
Improve speed of decision-making for cancer patients
Support treatment monitoring and resistance identification
| Sample Type | Plasma cDNA (BD PAXgene tube) + optional peripheral blood (K2EDTA) OR 1 FFPE tissue block (20–30% tumor content, ≤ 3–4 months old) |
| Sample Collection | Peripheral blood via butterfly needle or 22G syringe |
| Sample Volume | 2 PAXgene tubes + 1 K2EDTA tube OR 1 FFPE block |
| cfDNA/DNA Input Amount | >1 ng |
| Sequencing Platform | Illumina (2 × 150 bp paired-end) |
| Mean Sequencing Depth | 2000x / 10000x |
| Sequencing Chemistry | Hybrid capture |
| Indications | Clinically diagnosed cancers associated with OncoTarget® panels |
| Analysis Platform | iCare™ AI-based analysis and reporting |
| Cancer Type | Key Genes |
|---|---|
| Lung | EGFR, ALK, KRAS, ROS1, MET, RET, HER2, PIK3CA, BRAF |
| Breast | BRCA1, BRCA2, HER2, PIK3CA, ESR1, PALB2 |
| Colorectal | KRAS, NRAS, BRAF, ERBB2, PIK3CA, TP53 |
| GI | KIT, ALK, KRAS, NRAS, BRAF, ROS1, RET |
| Ovary | BRCA1, BRCA2, MTOR, MSI markers |
| Prostate | BRCA1, BRCA2, CHEK2, PALB2, RAD51D |
| Bladder | FGFR1, FGFR2, FGFR3, HER2, MSI markers |
| Melanoma | BRAF, NRAS, CDKN2A |
| Thyroid | BRAF, ALK, RET, NTRK1/2/3, MSI markers |
